Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

HER2/3 Across Solid Tumors: Toward Harmonization of Pathology and Oncology to Optimize Diagnosis and Management

Release Date: September 30, 2020
Expiration Date: Septembe 30, 2021

Activity Overview

For over 20 years, trastuzumab has been the foundation of therapy for patients with HER2+ breast cancer, and more recently several novel agents have emerged for continual improvement of treatment outcomes for these patients. HER2 amplification has been increasingly recognized as a frequent abnormality in not only breast cancers, but also gastrointestinal cancers, enabling oncologists to administer HER2/3-targeted therapies to these patients as well. Testing for HER2 is an important step in determining which patients will benefit from treatment with HER2-targeted agents. HER2 amplification and overexpression, however, are much more heterogeneous in gastrointestinal cancers compared with breast cancer, with incomplete membrane staining resulting in the need for an exclusive scoring and interpretation system for gastrointestinal tumor samples. While EGFR, another receptor related to HER2, has long been a target successfully treated in patients with non–small cell lung cancer, novel anti-HER2 agents have emerged to combat tumor resistance. Across tumor types, HER3 amplification may be an indication of treatment resistance, and targeting HER3 in addition to HER2 may be a novel way to specifically treat these tumors.
 
This online, on-demand virtual symposium brings together renowned experts who analyze tumors for HER2 status and who manage and treat patients with HER2-positive breast, gastrointestinal and lung cancers. In this educational program these experts will use a case-based format to discuss the latest data in regard to guidelines for HER2 testing of tumor biopsies, analysis of testing results, the rationale for utilizing HER2 testing in the treatment decision making process as well as review novel and emerging agents in the ever-expanding treatment landscape for patients with HER2-positive cancer. .

This educational activity is an archive of the live virtual symposium held on September 10, 2020.

Acknowledgement of Support

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward the ASCP audience of oncology pathologists. Other healthcare professionals involved in the diagnosis and treatment of cancer will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:
 
  • Describe diagnostic testing strategies and molecular mechanisms of disease that guide the use of novel and emerging HER2/3-targeted treatment strategies for breast, lung, and gastrointestinal cancers
  • Integrate available data regarding novel HER2/3 treatment paradigms into clinical scenarios for breast, lung, and gastrointestinal cancers
  • Apply multidisciplinary approaches that ensure diagnostic information related to HER2/3 are utilized along key clinical decision points along the cancer disease continuum

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
 

Faculty

Ami N. Rubinowitz, MD
Lynette M. Sholl, MD
Associate Professor of Pathology
Harvard Medical School
Associate Pathologist
Brigham and Women’s Hospital
Boston, MA
 

Disclosures: Consultant: EMD Serono

Jonathan H. Chung, MD
Pasi A. Jänne, MD, PhD
Director, Lowe Center for Thoracic Oncology
Professor of Medicine, Harvard Medical School
Director, Belfer Center for Applied Cancer Science
Dana Farber Cancer Institute
Boston, MA
 

Disclosures: Grant Research Support: AstraZeneca, Astellas; Consultant: AstraZeneca, Boehinger Ingelheim, Roche, Chugai, Merrimack, Pfizer and Ariad Pharmaceuticals; Speakers Bureau: Gatekeeper Pharmaceuticals; Other: Post marketing royalties on DFEI owned patent on EGFR mutations licensed to Lab Corp.

Michael A. Kadoch, MD
Jonathan A. Nowak, MD, PhD
Assistant Professor of Pathology
Brigham and Women’s Hospital
Boston, MA
 

Disclosures: Jonathan A. Nowak, MD, PhD has no relevant financial relationships with commercial interests to disclose. 

Lisa H. Lancaster, MD
Tiffany A. Traina, MD
Vice Chair, Oncology Care
Section Head, Triple Negative Breast Cancer Clinical Research Program
Clinical Director, Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, NY

Disclosures: Grant/Research Support: AstraZeneca, Astellas Pharama, Carick Pharmacy, Daiichi Sankyo, Eisai, Pfizer, Innocrin Pharma, Immunomedics, Novartis, Genentech/Roche; Consultant: Aduro Biotech, Advaxis, AstraZeneca, Athenex, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genentech, Genomic Health, Halozyme, Innocrin Pharma, Ionis, Merck, Pfizer, Puma Biotechnology, Samsung, Seattle Genetics; Speakers Bureau: Roche/Genentech

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By